Clinical trial · Interventional
An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy
Pilot Study of Metabolic Guidance for Therapy in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial investigates whether hyperpolarized magnetic resonance imaging (hpMRI) can predict treatment response in patients with thyroid cancer and other malignancies of the head and neck undergoing radiation therapy and/or receiving systemic therapy before surgery. An hpMRI is like a standard MRI but involves the use of an imaging contrast agent called hyperpolarized 13-C-pyruvate. Diagnostic procedures, such as hpMRI, may predict a patient's response to treatment and may help plan the best treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Gland Carcinoma | Thyroid Gland Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hyperpolarized Carbon C 13 Pyruvate | Drug | — | UNRESOLVED |
| Magnetic Resonance Imaging | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Arm I ( Health Volunteer MRI)
- description
- Healthy volunteers undergo MRI over 30 minutes.
- interventionNames
- Procedure: Magnetic Resonance Imaging
- type
- EXPERIMENTAL
- label
- Arm II (Thyroid Cancer Patient and other malignancies of the head and neck hpMRI)
- description
- Patients with thyroid cancer and other malignancies of the head and neck undergo hpMRI over 30 minutes at baseline, and at 1 week after the initiation of treatment. During the scan, patients also receive hyperpolarized 13-C-pyruvate IV over 30 seconds and may receive a standard MRI contrast agent at the discretion of the treating physician.
- interventionNames
- Drug: Hyperpolarized Carbon C 13 Pyruvate
- Procedure: Magnetic Resonance Imaging
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Be willing and able to provide informed consent * Be informed of the investigational nature of this study * Be diagnosed with thyroid cancer and other malignancies of the head and neck with intent for treatment Exclusion Criteria: * Have a history of severe claustrophobia * Have electrically, magnetically or mechanically activated implants that would preclude magnetic resonance imaging (MRI) * Have a history of cardiac arrhythmia * Have an allergy to Gadavist intravenous contrast * Estimated glomerular filtration rate (eGFR) \< 30 * If female, be pregnant or breast feeding at time of consent
References
Publications (0)
Data not yet available